Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Magnesium pills might sharpen your mind while treating depression

NCT ID NCT07521358

Symptom relief Sponsor: Hasanuddin University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether taking magnesium supplements alongside the antidepressant fluoxetine can improve cognitive function in adults with major depression. Forty participants took either fluoxetine plus magnesium or fluoxetine alone for six weeks. Researchers measured changes in thinking skills and a brain protein called BDNF. The goal is to see if magnesium offers an extra benefit for mental clarity.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Magnesium (dietary supplement)
What this could lead to
If it works, adding magnesium to standard depression treatment could help improve thinking and memory in people with depression.
What could go wrong
This is a very small, completed trial with only 40 people. Results may not apply to everyone, and magnesium might not provide any extra benefit beyond fluoxetine alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Jul 2025

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients aged 18-60 years * Diagnosed with major depressive disorder based on clinical assessment * Receiving fluoxetine therapy * Able to understand and provide informed consent Exclusion Criteria: * History of other major psychiatric disorders (e.g., schizophrenia, bipolar disorder) * Severe medical or neurological illness * Use of other psychotropic medications that may affect cognitive function * Known hypersensitivity to magnesium * Pregnancy or breastfeeding * Inability to complete cognitive assessment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive disorder (MDD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depressive disorder (MDD)

Contacts and locations

Locations

  • Dr. Wahidin Sudirohusodo Hospital

    Makassar, South Sulawesi, 90245, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.